Scholarlink

<p>The co-morbidity of psoriasis (PsO) and metabolic syndrome (MetS) is prevalent. While the mechanisms causing PsO in MetS remain unknown, it&#xa0;is understood&#xa0;that gut microbiota plays a critical role in maintaining immune and metabolic balance. However, the specific mechanisms and whether biomarkers are involved in the pathophysiological process of PSO in MetS patients have yet to&#xa0;be elucidated. This study involved 29 patients with PSO and MetS (PM) and 29 with MetS (M). It analyzed their clinical parameters, microbial composition, function, diagnostic, and predictive performance. The results unveiled significant differences between the two groups concerning microbial diversity and community composition. Most of the differential microbiota in the PM group exhibited a negative correlation with high-density lipoprotein (HDL) and a positive correlation with serum uric acid (SUA). In contrast, the opposite&#xa0;was observed&#xa0;in the M group. Sixteen MetaCyc pathways showed significance in the PM group, encompassing peptidoglycan biosynthesis II (staphylococci), the super pathway of L-arginine and L-ornithine degradation, teichoic acid (poly-glycerol) biosynthesis, and palmitic biosynthesis II (bacteria and plants). Six KEGG pathways&#xa0;were enriched&#xa0;in the M group, such as flavone, flavonol biosynthesis, and carotenoid biosynthesis.&#xa0;Most importantly, we determined that eight biomarkers, represented by <i>Akkermansia</i>, demonstrated robust diagnostic predictive power. This study elucidates the potential mechanism through which metabolic disorders impact the onset and progression of psoriasis via intestinal microbiota. Furthermore, it offers novel strategies for preventing, diagnosing, and treating PsO in MetS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characterization of intestinal microbiota in patients with psoriasis combined with metabolic syndrome

  • 期刊论文

  • 发表日期：

    2025年8月20日

查看全文
  • Yiyue Yuan,
  • Linna Zhao,
  • Haining Ding,
  • Yinshuang Hua,
  • Hongmei Wang,
  • Manlin Zhao

摘要

The co-morbidity of psoriasis (PsO) and metabolic syndrome (MetS) is prevalent. While the mechanisms causing PsO in MetS remain unknown, it is understood that gut microbiota plays a critical role in maintaining immune and metabolic balance. However, the specific mechanisms and whether biomarkers are involved in the pathophysiological process of PSO in MetS patients have yet to be elucidated. This study involved 29 patients with PSO and MetS (PM) and 29 with MetS (M). It analyzed their clinical parameters, microbial composition, function, diagnostic, and predictive performance. The results unveiled significant differences between the two groups concerning microbial diversity and community composition. Most of the differential microbiota in the PM group exhibited a negative correlation with high-density lipoprotein (HDL) and a positive correlation with serum uric acid (SUA). In contrast, the opposite was observed in the M group. Sixteen MetaCyc pathways showed significance in the PM group, encompassing peptidoglycan biosynthesis II (staphylococci), the super pathway of L-arginine and L-ornithine degradation, teichoic acid (poly-glycerol) biosynthesis, and palmitic biosynthesis II (bacteria and plants). Six KEGG pathways were enriched in the M group, such as flavone, flavonol biosynthesis, and carotenoid biosynthesis. Most importantly, we determined that eight biomarkers, represented by Akkermansia, demonstrated robust diagnostic predictive power. This study elucidates the potential mechanism through which metabolic disorders impact the onset and progression of psoriasis via intestinal microbiota. Furthermore, it offers novel strategies for preventing, diagnosing, and treating PsO in MetS.